美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Kailera Therapeutics, Inc.

17.89

+1.358.16%

成交量：99.93萬

成交額：1,759.88萬

市值：23.17億

市盈率：-7.94

高：18.18

開：16.75

低：16.54

收：16.54

52周最高：28.23

52周最低：16.37

股本：1.30億

流通股本：4,492.19萬

量比：1.13

換手率：2.22%

股息：- -

股息率：- -

每股收益(TTM):-2.2543

每股收益(LYR):-7,819.9811

淨資產收益率：-36.90%

總資產收益率：-22.73%

市淨率：2.07

市盈率(LYR):0.00

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Kailera Therapeutics旗下高劑量Ribupatide注射劑2b期臨床試驗完成全部入組；數據預計2027年中出爐

Kailera Therapeutics 向FDA提交Ribupatide口服活性IND申請，計劃2027年上半年啓動三期肥胖症臨床試驗

財報前瞻｜Kailera Therapeutics, Inc.管線進展提速，機構看多佔優

數據簡報-隨着小型企業不斷湧現，減肥藥的上市競爭日益白熱化

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/KLRA"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KLRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics, Inc.","latestPrice":17.89,"timestamp":1787685676640,"preClose":16.54,"halted":0,"volume":999299,"delay":0,"changeRate":0.08162031438935922,"floatShares":44921899,"shares":129537300,"eps":-2.254252,"marketStatus":"交易中","change":1.35,"latestTime":"08-25 15:21:17 EDT","open":16.75,"high":18.18,"low":16.54,"amount":17598830.565624,"amplitude":0.099154,"askPrice":17.92,"askSize":100,"bidPrice":17.88,"bidSize":499,"shortable":3,"etf":0,"ttmEps":-2.254252,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":16.54,"preHourTrading":{"tag":"盘前","latestPrice":16.82,"preClose":16.54,"latestTime":"09:12 EDT","volume":142,"amount":2396.5300239999997,"timestamp":1787663555308,"change":0.28,"changeRate":0.016929,"amplitude":0.000605},"postHourTrading":{"tag":"盘后","latestPrice":16.54,"preClose":16.54,"latestTime":"19:30 EDT","volume":1244,"amount":20603.54,"timestamp":1787614207306,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.128272},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","floatShares":44921899,"roa":"-22.73%","roe":"-36.90%","lyrEps":-7819.9811,"volumeRatio":1.128272,"shares":129537300,"dividePrice":0,"high":18.18,"amplitude":0.099154,"preClose":16.54,"low":16.54,"week52Low":16.37,"pbRate":"2.07","week52High":28.2271,"institutionHeld":0,"latestPrice":17.89,"committee":0.66611,"eps":-2.254252,"divideRate":0,"volume":999299,"delay":0,"ttmEps":-2.254252,"open":16.75,"prevYearClose":16,"prevWeekClose":17.17,"prevMonthClose":16.94,"prevQuarterClose":22.03,"fiveDayClose":17.83,"twentyDayClose":16.74,"sixtyDayClose":22.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"KLRA","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-1.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1783656000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRA","date":"2026-08-24","current":-7.936114,"percent":1,"low":-21.871461,"twenty":-19.582567,"median":-16.636224,"eighty":-11.274789,"high":-7.618086,"avg":-15.350689,"sd":4.227414,"marketCap":2225981916},"quantilePoints":[{"date":"2026-04-17","current":-12.669466,"twenty":-12.511098,"median":-12.273546,"eighty":-12.035993,"marketCap":1887180368},{"date":"2026-04-24","current":-20.824025,"twenty":-20.917019,"median":-20.433783,"eighty":-14.17085,"marketCap":3101842710},{"date":"2026-05-01","current":-21.741015,"twenty":-21.413894,"median":-20.305085,"eighty":-18.829635,"marketCap":3238432850},{"date":"2026-05-08","current":-19.540824,"twenty":-21.576784,"median":-20.824025,"eighty":-19.524523,"marketCap":2910703445},{"date":"2026-05-15","current":-18.697273,"twenty":-21.521865,"median":-20.058623,"eighty":-18.676401,"marketCap":2785052251},{"date":"2026-05-22","current":-18.332024,"twenty":-21.403595,"median":-19.540824,"eighty":-18.304195,"marketCap":2730646579},{"date":"2026-05-29","current":-19.949555,"twenty":-21.097481,"median":-19.520448,"eighty":-18.332024,"marketCap":2971585983},{"date":"2026-06-05","current":-18.253756,"twenty":-20.940268,"median":-19.530636,"eighty":-18.332024,"marketCap":2718988220},{"date":"2026-06-12","current":-16.992777,"twenty":-20.824025,"median":-19.392985,"eighty":-17.13192,"marketCap":2531159115},{"date":"2026-06-18","current":-16.636224,"twenty":-20.511831,"median":-18.758148,"eighty":-17.050173,"marketCap":2478048816},{"date":"2026-06-26","current":-12.75669,"twenty":-20.227867,"median":-18.684228,"eighty":-17.050173,"marketCap":2676825461},{"date":"2026-07-02","current":-12.855483,"twenty":-20.165517,"median":-18.622605,"eighty":-16.764931,"marketCap":2697555958},{"date":"2026-07-10","current":-12.9728,"twenty":-20.033041,"median":-18.410291,"eighty":-15.433812,"marketCap":2722173424},{"date":"2026-07-17","current":-11.311837,"twenty":-19.949555,"median":-18.314631,"eighty":-13.521103,"marketCap":2373641938},{"date":"2026-07-24","current":-10.743775,"twenty":-19.944337,"median":-17.453687,"eighty":-12.859187,"marketCap":2254441579},{"date":"2026-07-31","current":-10.527665,"twenty":-19.923466,"median":-17.13192,"eighty":-12.704356,"marketCap":2209093616},{"date":"2026-08-07","current":-11.651439,"twenty":-19.849563,"median":-17.071044,"eighty":-11.79378,"marketCap":2444903022},{"date":"2026-08-14","current":-7.973035,"twenty":-19.724778,"median":-16.992777,"eighty":-11.573639,"marketCap":2329696857},{"date":"2026-08-21","current":-7.746755,"twenty":-19.603438,"median":-16.640572,"eighty":-11.334065,"marketCap":2263578582},{"date":"2026-08-24","current":-7.618086,"twenty":-19.582567,"median":-16.636224,"eighty":-11.274789,"marketCap":2225981916}],"updateTime":1787685677563},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRA\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1180540299","title":"Kailera Therapeutics旗下高劑量Ribupatide注射劑2b期臨床試驗完成全部入組；數據預計2027年中出爐","url":"https://stock-news.laohu8.com/highlight/detail?id=1180540299","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180540299?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 04:45","pubTimestamp":1786567521,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics（股票代码：KLRA，公司全称：Kailera Therapeutics, Inc.）近日宣布，其正在进行的高剂量Ribupatide注射剂2b期临床试验已完成全部患者入组工作。这一里程碑标志着该研究迈入关键阶段。根据公司规划，相关试验数据预计将在2027年年中正式发布。Ribupatide作为一款备受关注的注射剂候选药物，此次高剂量方案的研究结果将为其后续临床开发提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","BK4139","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198856529","title":"Kailera Therapeutics 向FDA提交Ribupatide口服活性IND申請，計劃2027年上半年啓動三期肥胖症臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1198856529","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198856529?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 04:44","pubTimestamp":1786567448,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics 公司已正式向美国食品药品监督管理局（FDA）提交了关于Ribupatide口服活性成分的研究性新药（IND）申请。与此同时，该公司规划在2027年上半年，启动针对肥胖症的三期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129975436","title":"財報前瞻｜Kailera Therapeutics, Inc.管線進展提速，機構看多佔優","url":"https://stock-news.laohu8.com/highlight/detail?id=1129975436","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129975436?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 08:56","pubTimestamp":1785891370,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics, Inc.将于2026年08月12日美股盘后发布最新财报，市场关注其管线推进与费用节奏对亏损幅度与每股收益的影响。公司披露，该项目在大中华区外的权益归属Kailera，并同步推进全球II期试验，为后续多区域III期转化与注册策略铺路。综合各家覆盖结论，当前市场对Kailera的核心分歧在时间维度：管线价值的兑现速度与费用峰值出现时点。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Kailera Therapeutics, Inc.管线进展提速，机构看多占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649939231","title":"數據簡報-隨着小型企業不斷湧現，減肥藥的上市競爭日益白熱化","url":"https://stock-news.laohu8.com/highlight/detail?id=2649939231","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649939231?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 00:13","pubTimestamp":1783440834,"startTime":"0","endTime":"0","summary":"数据简报-随着小型企业不断涌现，减肥药的上市竞争日益白热化在第1、2和25段中补充了Kailera Therapeutics公司肥胖症药物的详细信息路透7月7日-凯莱拉制药的KLRA.O口服减肥药在中国开展的一项晚期临床试验中，帮助患者在第44周时减重 ，最高可达体重的10.9%。这两种药物目前均处于临床前试验阶段。华东制药中国华东制药公司的口服减肥候选药物HDM1002，在中国针对超重或肥胖受试者进行的一项早期研究中，使体重最多减少了6.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4T4391IA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836591.USD","SG9999013999.USD","IE00B19Z3581.USD","LU2108987350.USD","LU1551013342.USD","LU1712237335.SGD","LU2112291526.USD","LU0109394709.USD","LU2089283258.USD","LU2491049909.HKD","KLRA","LU1923622614.USD","IE00BK4W5L77.USD","LU2023250330.USD","BK4592","LU1162221912.USD","LU1934455194.USD","LU1430594728.SGD","LU2125909247.SGD","LLYX","LU2237443549.SGD","LU0323591593.USD","IE00B4R5TH58.HKD","01672","LU0158827948.USD","SG9999015341.SGD","LU0306806265.USD","LU1883839398.USD","LU1720051017.SGD","LU0133085943.USD","LU2097828557.USD","SGXZ31699556.SGD","LU0353189763.USD","GB00BDT5M118.USD","BK4532","LU1037948541.HKD","LU0353189680.USD","LU0265550946.USD","LU0466842654.USD","LU0225284248.USD","IE00B3T34201.USD","LU0006306889.USD","LU0211331839.USD","LU2461242641.AUD","03692","LU0256863811.USD","PFE","IE0004445015.USD","SG9999015978.USD","LU0417517546.SGD","LU0820561909.HKD","SG9999015358.SGD","LU2746668974.SGD","LU0683600562.USD","AZNH","LU1035775433.USD","LU0079474960.USD","SG9999015945.SGD","LU2552382132.HKD","SG9999003800.SGD","PPH","LU1280957306.USD","LU2552382058.USD","LU2750360997.AUD","LU1868836914.USD","MEDX","IE00BFSS7M15.SGD","LU1201861249.SGD","LU1291159041.SGD","LU2237443895.HKD","LU2360106947.USD","LU1868837300.USD","LU2596442595.SGD","SG9999011175.SGD","LU1069347547.HKD","LU2456880835.USD","FTXH","LU0321505439.SGD","LU0225771236.USD","LU2357305700.SGD","LU2023250843.SGD","LU0114720955.EUR","LU1969619763.USD","IE00BLSP4452.SGD","PJP","LU2106854487.HKD","LU0672654240.SGD","LU0198837287.USD","IHE","IE0002270589.USD","LU2111349929.HKD","VHT","LLII","LU2471134879.HKD","LU2471134796.USD","THNR","LU2360032135.SGD","IE00BJLML261.HKD","LU1232071149.USD","SG9999014914.USD","IE00BSNM7G36.USD","LU0942090050.USD","LU1093756168.USD","LU0266013472.USD","LU2242644610.SGD","IE00BLSP4239.USD","LU1571399168.USD","BK4007","LU1934455863.HKD","BK4139","LU0061475181.USD","LU1093756325.SGD","PAWZ","SGXZ57979304.SGD","LU0965509283.SGD","LU0265550359.USD","LU2265009873.SGD","LU2237443465.HKD","LU2417539215.USD","SG9999014880.SGD","LU2491050071.SGD","BK1589","LU0868494708.USD","LU2271345857.HKD","LU0289739699.SGD","IE0009355771.USD","BK4599","LU0786609619.USD","LU1814569148.SGD","LU1267930730.SGD","01801","LU2023250504.SGD","LU1699723380.USD","LU0154236417.USD","LU2168564149.EUR","LU0345770308.USD","LU0861579265.USD","BK4568","LU1941712264.USD","LU0943347566.SGD","LU0029864427.USD","LU0882574139.USD","LU0985481810.HKD","LU0965508806.USD","BK1161","LU0158827781.USD","JDOC","LU0210536198.USD","LU1066051225.USD","SG9999014906.USD","IE00B7KXQ091.USD","SG9999014567.USD","LU1929549753.HKD","LU0640476718.USD","VKTX","SG9999014559.SGD","LU1037948897.HKD","BK4550","IE0004445239.USD","IE00BWXC8680.SGD","LU0456855351.SGD","LU0965509101.SGD","LU2236285917.USD","LU2491050154.USD","LU2896262040.SGD","LU0130102774.USD","LU0225283273.USD","LU1061106388.HKD","BK4559","LU1804176565.USD","LU2328871848.SGD","LU1057294990.SGD","LU0208291251.USD","LU2756315664.SGD","LU0238689110.USD","IE00B4JS1V06.HKD","SG9999018857.SGD","HRTS","LU0130517989.USD","SG9999001176.USD","SGXZ99366536.SGD","LU2237443382.USD","ELIL","BK4534","LU0648001328.SGD","LU1551013425.SGD","LU0889565916.HKD","LU2023251221.USD","LU0868494617.USD","LU2433249047.HKD","LU1323610961.USD","IE00B19Z3B42.SGD","LU1983299246.USD","LU0096364046.USD","LU0320765992.SGD","LU0256863902.USD","LU1116320901.HKD","SGXZ51526630.SGD","LU0310800379.SGD","LU2264538146.SGD","ELIS","NVOX","LU2028103732.USD","LU0203347892.USD","MEDI","LU0980610538.SGD","LU1267930573.SGD","LLY","LU0820562030.AUD","SG9999018865.SGD","LU2237443622.USD","CURE","NVO","GPCR","LU2097828474.EUR","LU2087625088.SGD","LU0320765059.SGD","LU0203201768.USD","LU1941712348.USD","IE00BJJMRY28.SGD","SG9999002232.USD","LU0882574055.USD","GDOC","IXJ","LU0385154629.USD","RXL","SGXZ81514606.USD","LU2602419157.SGD","LU0689472784.USD","SG9999017495.SGD","LU0708995401.HKD","LU0477156953.USD","LU1035773651.USD","LU1127390331.HKD","IE00BFSS8Q28.SGD","LU2237438978.USD","LU2361045086.USD","LU1066053197.SGD","LU0203202063.USD","LU1934455277.USD","IE00B1BXHZ80.USD","IE0001KFT4U8.USD","LU0965509010.AUD","LU2746668461.USD","LU0321505868.SGD","BK1515","LU1116320737.USD","LU2213496289.HKD","SG9999014575.USD","LU2168564495.EUR","LU0106261372.USD","LU0985320562.USD","CANC","IE00BZ1G4Q59.USD","LU0964807845.USD","BK1574","LU0128525929.USD","NVOH","SG9999002224.SGD","AZN","IE00BKDWB100.SGD","BK4581","LU0097036916.USD","IE00BJJMRX11.SGD","SG9999015986.USD","SG9999001176.SGD","BK1583","IYH","LU0471298777.SGD","LU0122379950.USD","LU0471298694.HKD","LU0354030438.USD","LU0320765646.SGD","LLYZ","IE00B1XK9C88.USD","LU0320765489.SGD","LU1064131342.USD","LU0094547139.USD","LU2462157665.USD","LU1585245621.USD","LU1145028129.USD","LU1917777945.USD","IE00BKVL7J92.USD","LU1066051811.HKD","LU0823434740.USD","LU1989772840.SGD","LU2361044865.SGD","IE00BFTCPJ56.SGD","LU0455707207.USD","LU0432979614.USD","LU0859254822.USD","FHLC","OZEM","SG9999001440.SGD","IE00BBT3K403.USD","LU1894683348.USD","LU2125909593.SGD","LU2089984988.USD","LU0787776722.HKD","LU2125154935.USD","BK1191","LU2471134952.CNY","SG9999014898.SGD","BMED","MRK","LU0098860793.USD","IE00BN29S564.USD","IE00BKPKM429.USD","SG9999015952.SGD","LU1548497426.USD","LU1894683264.USD","IE00BK4W5M84.HKD","LU1989771016.USD","LU2089284900.SGD","LU2357627491.SGD","XLV","LU1868836757.USD","LU0170899867.USD","BK4588","LU0354030511.USD","LU2097828631.EUR","LU1623119135.USD","LU1366192091.USD","LU0820561818.USD","LU0823434583.USD","BK4585","BK4516","LU2168563687.JPY","LU1868837136.USD","LU0234572021.USD","LU2552382215.SGD","IE0002141913.USD","HK0000165453.HKD","IE00BJJMRZ35.SGD","LU2168564065.EUR","LU2471134523.USD","LU2488822045.USD","LU1988902786.USD","WDNA","LU2361044949.HKD","LU0316494557.USD","LU1989772923.USD","KURE","LU0345770993.USD","LU0203345920.USD","SG9999014542.SGD","IE00B775H168.HKD","LU2168564222.USD","BK4533","LU2063271972.USD","LU1829250122.USD","IE00B2B36J28.USD","LU2324357040.USD","LU0306807586.USD","LU0058720904.USD","LU2756315318.SGD","IE00BN8TJ469.HKD","LU0502904849.HKD","AGNG","LU2097828714.EUR","IE000M9KFDE8.USD","LU2237443978.SGD","LU2468319806.SGD","LU0708994859.HKD","ILDR","LU1023059063.AUD","LU2097828805.USD","LU1974910355.USD","LU0823416689.USD","LU2211815571.USD","IE00BJT1NW94.SGD","LU1066051498.USD","IE0005OL40V9.USD","LU2125154778.USD","LU0070302665.USD","LU1720051108.HKD","LU1069344957.HKD","LU2750360641.GBP","LU1629891620.HKD","LU0109391861.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/KLRA\",params:#limit:6,delay:false,,,undefined,":[]}}